Complications Associated With Revision of Sprint Fidelis Leads

Report From the Canadian Heart Rhythm Society Device Advisory Committee

Ratika Parkash, MD, MSc; Eugene Crystal, MD; Jamil Bashir, MD; Christopher Simpson, MD; David Birnie, MD; Laurence Sterns, MD; Derek Exner, MD; Bernard Thibault, MD; Sean Connors, MD; Jeffrey S. Healey, MD, MSc; Jean Champagne, MD; Doug Cameron, MD; Iqwal Mangat, MD; Atul Verma, MD; Kevin Wolfe, MD; Vidal Essebag, MD, PhD; Teresa Kus, MD; Felix Ayala-Paredes, MD; Ted Davies, MD; Shubhayan Sanatani, MD; Robert Gow, MB, BS; Benoit Coutu, MD; Soori Sivakumaran, MD; Elizabeth Stephenson, MD; Andrew Krahn, MD

Background—It has been observed that replacement of an implantable cardioverter-defibrillator generator in response to a device advisory may be associated with a substantial rate of complications, including death. The risk of lead revision in response to a lead advisory has not been determined previously.

Methods and Results—Twenty-five implantable cardioverter-defibrillator implantation and follow-up centers from the Canadian Heart Rhythm Society Device Advisory Committee were surveyed to assess complication rates as a result of lead revisions due to the Sprint Fidelis advisory issued in October 2007. As of June 1, 2009, there had been 310 lead failures found in 6237 Sprint Fidelis leads in Canada (4.97%) over a follow-up of 40 months. There were 469 leads to be revised, 66% for confirmed fracture. Of the patients who underwent revision, 95% had a new lead inserted, whereas 4% had a pace/sense lead added. The lead was removed in 248 cases (53%), by simple traction in 61% and by laser lead extraction in 33%. Complications were encountered in 14.5% of the lead revisions; 7.25% of these were major, whereas 7.25% were minor. There were 2 deaths (0.43%). The overall risk of complications (19.8%) was greater in those who underwent lead removal at the time of revision than in those whose leads were abandoned (8.6%; P=0.0008).

Conclusions—The overall rate of major complications that arose from lead revision due to the Sprint Fidelis advisory was significant. This must be taken into account when lead revision is planned in those patients who have not yet demonstrated an abnormality in lead performance. (Circulation. 2010;121:2384-2387.)

Key Words: complications ■ follow-up studies ■ implantable defibrillators

The Canadian Heart Rhythm Society Device Advisory Committee has reported previously on the increased risk of generator replacement associated with device advisories.1,2 The Sprint Fidelis lead advisory was issued in October 20073 and affected 6415 leads in Canada and 245,000 worldwide.4 The rate of fracture was initially thought to be approximately 1% to 1.5% per year, accelerating to approximately 3% at 30 months.3 Recent data suggest the risk increases by 2.74-fold per year after implantation and that the risk is higher than originally projected.5

Up to 50% of patients with lead fractures may present with inappropriate shocks, some with severe psychological impairment due to the number of shocks received.5 Lead Integrity Alert software (Medtronic, Minneapolis, Minn) only recently became available in Canada and has reduced the incidence of this kind of presentation.6 Routine prophylactic replacement of the Sprint Fidelis lead has not been practiced widely owing to the known risks associated with lead revision, which include infection, hematoma, and, in the case of laser lead extraction, a 0.5% to
2.0% mortality risk. Lead replacement at the time of pulse generator replacement is often considered and has been practiced widely. Given the increasing risk of lead failure, prophylactic replacement of all Sprint Fidelis leads has also been considered. The decision to replace a lead routinely or at generator replacement must include a weighing of the risks of lead revision against the risks of lead failure. Using an established cross-country network, the Canadian Heart Rhythm Society Device Advisory Committee sought to determine the complications associated with lead revision in the Canadian cohort of Sprint Fidelis lead recipients to provide guidance in this matter.

Methods
All 25 Canadian implantable cardioverter-defibrillator implantation centers were approached to participate in a survey of outcomes of the Fidelis lead advisory. The Queen Elizabeth II Health Sciences Ethics Review Board approved the study. All centers agreed to participate in the survey process and obtained ethics approval if necessary in each respective center. Only leads that were followed up in Canada were included (n = 6237).

Survey
The survey questionnaire was circulated to a working group identified to review it for clarity, content, and ease of use. The working group arrived at the final survey through consensus. The data collected in the survey were divided into 4 areas: (1) Frequency of lead failure, including inappropriate shocks; (2) success and failure of lead removal, including laser lead extraction versus simple traction; (3) the reason for revision (lead fracture, at the time of pulse generator change, preventively for pacemaker dependence, secondary prevention, or other reasons); and (4) follow-up data related to complications.

Definitions
Lead failure was defined as nonphysiological high-rate sensing with a high pacing impedance that suggested fracture, a sudden change in sensing or pacing impedance, or a rise in high-voltage impedance that suggested coil fracture that led to a decision to perform lead replacement, as described previously.4 The local investigator at each center identified whether or not a lead was fractured.

Outcomes
The main outcome of this survey was complication rate as a result of lead revision associated with the Sprint Fidelis lead. Early (≤30 days) and late (>30 days) complications were recorded, along with details of the nature of complications observed. Determination of whether or not the lead was removed successfully was taken into account for each complication. Major complications after or during lead revision included death, cardiac arrest, nonfatal myocardial infarction, cardiogenic shock, and any other complications that required reoperation. Minor complications included pneumothorax, deep venous thrombosis, incisional infection, and wound hematoma that did not require reoperation, as well as any other complication not already classified as a major complication.

Statistical Analysis
Continuous variables were analyzed as mean ± SD. Categorical variables were analyzed as percentages unless otherwise specified. Differences among groups were determined with the \( \chi^2 \) test; \( P < 0.05 \) was considered statistically significant.

Results
Data were obtained from 25 implantable cardioverter-defibrillator implantation and follow-up centers, which represented all 6237 Sprint Fidelis leads implanted from market release (July 2004) until product withdrawal (October 2007) and followed up in Canada. As of June 1, 2009, there were 310 leads with lead failures (4.97%) over an estimated 40 months of follow-up, 145 of which resulted in inappropriate shocks (3.1% overall, 43.0% of all fractures).

A further 159 leads were revised for other reasons (Table 1), which resulted in 469 leads (7.52%) that were deemed to be revised. Of these, a new defibrillation lead was inserted in 443 cases (94.5%), whereas in 25 cases (5.3%), only a pace/sense lead was added. In 1 case of confirmed fracture, the patient refused to have a revision, which left 468 leads that underwent revision. The lead was explanted in 248 cases (53%); this was done by simple traction in 163 cases (66%), by laser lead extraction in 82 cases (33%), and with nonpowered extraction tools in 3 cases (1%). Failed traction without formal lead extraction led to lead abandonment in an additional 51 patients (11%). No attempt at removal was made in the remainder of the patients (n = 169).

Complications
Complications are summarized in Table 2. The total number of complications was 68, which resulted in a rate of 14.5% of total leads revised. There were 34 major complications (7.25%) and 34 minor complications (7.25%).

Major Complications
The major complications included death in 2 cases (0.43%), cardiac arrest in 2 cases (0.43%, both successfully resuscitated), superior vena cava tear requiring urgent surgery in 1 case (0.21%), and a complication that required reoperation in 29 cases (6.23%). The 2 deaths occurred early postoperatively. One was due to pneumonia in a patient whose lead was abandoned, and this death was not directly related to the procedure; the second was due to postoperative sepsis after reoperation for a wound hematoma in a patient whose lead had been removed.

Minor Complications
The minor complications included incisional infection in 19 patients who did not require intervention and were treated with antibiotics (3.84%), wound hematoma in 7 patients (1.49%), and other causes in 9 patients (1.92%). There was a greater rate of overall complications observed in procedures in which a lead was removed than in those in which the lead was abandoned (19.8% versus 8.6%, \( P = 0.0008 \); Figure). The
Table 2. Complications Associated With Sprint Fidelis Revision

<table>
<thead>
<tr>
<th>Complications</th>
<th>Lead Removed (n=248)</th>
<th>Lead Abandoned (n=220)</th>
<th>All (n=468)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>49 (19.8)</td>
<td>19 (8.6)</td>
<td>68 (14.5)</td>
</tr>
<tr>
<td>Major complications</td>
<td>20 (8.1)</td>
<td>13 (5.9)</td>
<td>33 (7.0)</td>
</tr>
<tr>
<td>Death</td>
<td>1 (0.4)</td>
<td>1 (0.5)</td>
<td>2 (0.43)</td>
</tr>
<tr>
<td>Cardiac arrest</td>
<td>1 (0.4)</td>
<td>1 (0.5)</td>
<td>2 (0.43)</td>
</tr>
<tr>
<td>Need for reoperation</td>
<td>18 (7.3)</td>
<td>11 (5.0)</td>
<td>29 (6.2)</td>
</tr>
<tr>
<td>SVC tear during laser lead extraction</td>
<td>1 (0.4)</td>
<td>0</td>
<td>1 (0.21)</td>
</tr>
<tr>
<td>Infection that required system removal</td>
<td>7 (2.8)</td>
<td>2 (0.9)</td>
<td>9 (1.9)</td>
</tr>
<tr>
<td>Hematoma that required intervention</td>
<td>4 (1.6)</td>
<td>0</td>
<td>4 (0.9)</td>
</tr>
<tr>
<td>Lead dislodgement/set screw</td>
<td>6 (2.4)</td>
<td>9 (4.1)</td>
<td>15 (3.2)</td>
</tr>
<tr>
<td>Minor complications</td>
<td>29 (11.7)</td>
<td>6 (2.8)</td>
<td>35 (7.5)</td>
</tr>
<tr>
<td>Pneumothorax</td>
<td>3 (1.2)</td>
<td>0</td>
<td>3 (0.64)</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>0</td>
<td>1 (0.5)</td>
<td>2 (0.43)</td>
</tr>
<tr>
<td>DVT of left arm</td>
<td>2 (0.8)</td>
<td>0</td>
<td>2 (0.43)</td>
</tr>
<tr>
<td>Infection that did not require system removal</td>
<td>16 (6.5)</td>
<td>3 (1.4)</td>
<td>19 (4.1)</td>
</tr>
<tr>
<td>Hematoma that did not require intervention</td>
<td>6 (2.4)</td>
<td>1 (0.5)</td>
<td>7 (1.5)</td>
</tr>
<tr>
<td>Other (anemia, desaturation)</td>
<td>1 (0.4)</td>
<td>1 (0.5)</td>
<td>2 (0.43)</td>
</tr>
</tbody>
</table>

SVC indicates superior vena cava; DVT, deep venous thrombosis. Values are n (%).

rate of major complications, however, was similar in those patients whose leads were not removed (5.9% versus 8.1% in patients whose lead was removed, P=0.1826). Minor complications were more common in the group in whom the lead was removed (11.7% versus 2.8%, P=0.0003). There was no difference in mortality between the 2 groups (0.45% for lead removed versus 0.40% for lead not removed, P=0.8314).

Discussion

In this national survey, we report the complications associated with revisions that have occurred in response to the Sprint Fidelis advisory issued in October 2007. Since that time, there have been a substantial number of failures of this lead, now amounting to 4.97% over 40 months. At this point in time, the overall complication rate (among patients undergoing lead revision) of 14.5% is higher than the Sprint Fidelis failure rate, as is the 7.25% major complication rate, which in the present series included death, cardiac arrest, and complications that resulted in reoperation. The overall mortality rate among patients whose leads were removed was not significantly different from that of those whose leads were left in place.

This is the first study to systematically report on the complication rate that results from lead revision due to an advisory. The overall complication rate was marginally higher than what has been reported in the most recent REPLACE registry results. The total percentage of complications after generator change was 10.9% in that study, with major complications accounting for 4.2%. The higher rate of complications seen in the present study cohort is not unexpected, because the nature of the procedures was considerably more complex than simple generator replacement. Nearly 100% of patients underwent a lead revision with a new lead inserted, and in 17% of cases, a laser lead extraction was performed. The mortality rate in those who underwent lead extraction was similar to what has been reported in the literature.

There are several issues that must be highlighted in interpretation of the observed complication rate. Some of the centers that performed laser lead extraction were low-volume extraction centers; hence, some of the observed complications may not have occurred had the procedures been performed at higher-volume extraction centers. Hauser and Hayes10 reported 1 complication of pocket infection in 90 patients who underwent lead extraction as a result of the Sprint Fidelis advisory at 2 high-volume centers. Patient-specific data on lead age before extraction were not available in the present study. Presumably, those leads that were extracted earlier after implantation may have been easier to remove, whereas older leads would be more likely to require formal extraction, with an associated increase in complications. It is difficult to interpret whether this was the case because of the overall small number of complications in patients who underwent laser lead extraction. Finally, the indication for lead extraction may have been responsible for the observed complications, rather than the extraction itself.

Arrhythmia device management has become increasingly complex in the face of the recent increase in the number of advisories. Decision making surrounding these advisories can be extraordinarily difficult, because the data to judge the risk-benefit association for the affected patients often are not available. The Canadian Heart Rhythm Society Device Advisory Committee has reported previously that the risk of complications outweighed the benefit in response to a device generator advisory.1,2 In the present case, the answer may not be as straightforward. Although the risk of major complications is substantial, the risk of lead failure is approaching the same rate. Presumably, the complication rate remains static or may even decrease as we become more aware of the risks associated with such procedures and take further precautions to avoid hematomas, infections, and other issues that result in reoperation. It remains unclear how to treat a confirmed fracture or how to treat those patients undergoing a generator change or other lead revision.

There are 2 questions that remain difficult to answer: How should patients who have no sign of fracture be handled? Should
pamcaker-dependent patients or patients at high risk of recur-
rent implantable cardioverter-defibrillator therapy undergo pro-
phylactic lead revision? The data from this report suggest that
consideratons or age of the lead that may have contributed to
compli-
ations were not explored. The balance of time-dependent lead
failure and progressive lead fibrosis suggests that the challenge
of lead removal will increase over time, necessitating formal
lead extraction with its attendant risks. This balance must be
considered in patients with high use of their lead, including
pacemaker-dependent patients. Future studies are required to
inform this challenging decision-making process. Lead abandon-
ment was associated with fewer complications in the present
report. Follow-up was limited to 40 months, and therefore, data
on late complications that might occur from lead abandonment,
such as venous thrombosis, stenosis, or a higher risk of late
lead extraction, were not captured.

Conclusions
The risk of complications associated with lead revision due to
an advisory is significant. Given the increasing prevalence of
lead failure associated with this advisory, however, revision
at the time of pulse generator change or other intervention
resulting in opening of the pocket may be warranted. Further
data on risk factors for lead fracture will be helpful in
advising patients of the risk and benefit associated with
replacing leads affected by an advisory.

Disclosures
Dr Parkash has received research grants from Medtronic Inc and St
Jude Medical. Drs Crystal, Exner, and Thibault have received grant
support from Medtronic, St Jude Medical, Boston Scientific, and
Sorin/ELA. Dr Birnie has received grant support from Medtronic. Dr
Verma has received honoraria and research grants from St Jude
Medical, Biosense Webster, Medtronic Inc, Sanofi Aventis, and
Boehringer-Ingelheim. Dr Essebag has received honoraria and
minor speaker fees from Medtronic Inc. Dr Sanatani has received honoraria
from Medtronic. The remaining authors report no conflicts.

References
1. Gould PA, Krahn AD. Complications associated with implantable
cardioverter-defibrillator replacement in response to device advisories.
2. Gould PA, Gula LJ, Champagne J, Healey JS, Cameron D, Simpson C,
Thibault B, Pinter A, Tung S, Sterns L, Birnie D, Exner D, Parkash R,
Skanes AC, Yee R, Klein GJ, Krahn AD. Outcome of advisory
implantable cardioverter-defibrillator replacement: one-year follow-up.
3. Urgent Medical Device Information: Sprint Fidelis Lead Patient Management
4. Krahn AD, Champagne J, Healey JS, Cameron D, Simpson CS, Thibault
B, Mangat I, Tung S, Sterns L, Birnie DH, Exner DV, Parkash R,
Sivakumaran S, Davies T, Coutu B, Crystal E, Wolfe K, Verma A,
Stephenson E, Sanatani S, Gov R, Connors S, Paredes FA, Essebag V.
Outcome of the Fidelis implantable cardioverter-defibrillator lead
advisory: a report from the Canadian Heart Rhythm Society Device
5. Farwell D, Green MS, Lemery R, Gollob MH, Birnie DH. Accelerating
6. Swerdlov CD, Gunderson BD, Ousdigian KT, Abeyratne A, Stadler RW,
Gillberg JM, Patel AS, Ellenbogen KA. Downloadable algorithm to
reduce inappropriate shocks caused by fractures of implantable
Reiser C. Initial experience with larger laser sheaths for the removal of
transvenous pacemaker and implantable defibrillator leads. Circulation.
1999;100:516–525.
8. Byrd CL, Wilkoff BL, Love CJ, Sellers TD, Reiser C. Clinical study of
the laser sheath for lead extraction: the total experience in the United
V, Dan D, Shinn T, Poole J. Complication rates associated with
pacemaker and implantable defibrillator generator replacement: results
from the REPLACE Registry. Presented at: Heart Rhythm 2009 Scientific
Sessions (Late-Breaking Clinical Trials); May 14, 2009; Boston, Mass.
10. Hauser RG, Hayes DL. Increasing hazard of Sprint Fidelis implantable

CLINICAL PERSPECTIVE
It has been observed that implantable cardioverter-defibrillator generator replacement in response to a device advisory may be
associated with a substantial rate of complications, including death. We sought to determine the risk of lead revision in response
to a lead advisory, which has not been determined previously. Twenty-five implantable cardioverter-defibrillator implantation
and follow-up centers from the Canadian Heart Rhythm Society Device Advisory Committee were surveyed to assess
complications rates as a result of lead revision due to the Sprint Fidelis advisory issued in October 2007. Complications were
encountered in 14.5% of the lead revisions. There were 2 deaths (0.43%). The overall risk of complications (19.8%) was greater
among those who underwent lead removal at the time of revision than among those whose leads were abandoned (8.6%;
$P=0.0008$). The risk of complications associated with lead revision due to an advisory is significant. Given the increasing
prevalence of lead fracture associated with this advisory (4.97%), however, revision at the time of pulse generator change or other
intervention that results in opening of the pocket may be warranted. The present data suggest that lead abandonment at the time
of revision may be associated with a lower complication rate. Further data on risk factors for lead fracture will be helpful in
advising patients of the risk and benefit in replacing leads affected by an advisory.
Complications Associated With Revision of Sprint Fidelis Leads: Report From the Canadian Heart Rhythm Society Device Advisory Committee

Ratika Parkash, Eugene Crystal, Jamil Bashir, Christopher Simpson, David Birnie, Laurence Sterns, Derek Exner, Bernard Thibault, Sean Connors, Jeffrey S. Healey, Jean Champagne, Doug Cameron, Iqwal Mangat, Atul Verma, Kevin Wolfe, Vidal Essebag, Teresa Kus, Felix Ayala-Paredes, Ted Davies, Shubhayan Sanatani, Robert Gow, Benoit Coutu, Soori Sivakumaran, Elizabeth Stephenson and Andrew Krahn

_Circulation_. 2010;121:2384-2387; originally published online May 24, 2010; doi: 10.1161/CIRCULATIONAHA.109.924357

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2010 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/121/22/2384

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org/subscriptions/